The global De-Identified Health Data Market was valued at USD 8.8 billion in 2025 and is projected to grow from USD 9.6 billion in 2026 to USD 17.9 billion by 2033, expanding at a CAGR of 9.4% from 2026 to 2033. North America accounted for the largest revenue share of 35.3% in 2025, supported by its advanced healthcare infrastructure, strong regulatory ecosystem, and widespread adoption of digital health technologies.
The increasing use of healthcare analytics, artificial intelligence (AI), and real-world evidence (RWE) is accelerating demand for de-identified health data across healthcare organizations, life sciences companies, and research institutions. By removing personally identifiable information while preserving the analytical value of clinical datasets, de-identified health data enables organizations to conduct large-scale research, predictive modeling, and treatment analysis without compromising patient privacy. As healthcare systems continue generating massive volumes of electronic health records (EHRs), medical imaging, genomics, and wearable device data, the need for secure, privacy-compliant datasets is becoming increasingly important.
The rapid evolution of precision medicine and evidence-based healthcare is further strengthening market growth. Pharmaceutical companies, biotechnology firms, academic institutions, and contract research organizations increasingly rely on de-identified datasets to identify disease patterns, optimize clinical trials, validate biomarkers, and evaluate long-term treatment outcomes. These datasets also support health economics and outcomes research (HEOR), enabling organizations to assess healthcare utilization, cost-effectiveness, and patient outcomes across diverse populations.
Growing collaboration between healthcare providers, technology companies, and research institutions is creating new opportunities for data-driven innovation. For instance, Philips collaborated with the MIT Institute for Medical Engineering and Science (IMES) to develop an enhanced critical care dataset containing de-identified ICU patient information. The initiative supports AI model development, clinical research, and medical education while maintaining strict patient confidentiality. Similar collaborations are expected to accelerate the development of next-generation diagnostics, predictive analytics, and personalized treatment pathways.
Another major industry trend is the emergence of privacy-enhancing technologies (PETs), including federated learning, synthetic data generation, secure multiparty computation, and advanced anonymization techniques. These technologies enable organizations to extract greater analytical value from healthcare data while minimizing privacy risks and supporting compliance with evolving global regulations. As AI adoption expands, these privacy-preserving technologies are expected to become integral components of future healthcare data ecosystems.
The growing adoption of wearable health devices, remote patient monitoring systems, digital therapeutics, and connected medical devices is also expanding the volume of health data available for secondary analysis. Combined with cloud computing and interoperable healthcare platforms, these technologies are enabling continuous data collection that supports disease surveillance, preventive healthcare strategies, and population health management. As healthcare providers increasingly shift toward value-based care models, de-identified health data is becoming an essential resource for improving clinical decision-making and optimizing healthcare delivery.
Key Market Trends & Insights
- North America de-identified health data market dominated with a 35.3% revenue share in 2025. The region benefits from mature healthcare infrastructure, extensive adoption of AI-driven healthcare analytics, and strong regulatory frameworks such as HIPAA that promote secure use of healthcare data for research while protecting patient privacy.
- By type of data, the clinical data segment accounted for the largest market share of 17.0% in 2025. Clinical datasets remain the most valuable resource for treatment evaluation, disease progression analysis, clinical decision support, and personalized medicine initiatives across healthcare organizations.
- By application, the clinical research & trials segment held the largest revenue share in 2025. Growing adoption of decentralized clinical trials, adaptive trial designs, and real-world evidence studies continues to increase demand for privacy-compliant clinical datasets for patient recruitment, protocol optimization, and trial feasibility assessments.
- By end use, the healthcare providers segment dominated the market in 2025. Healthcare organizations increasingly utilize de-identified health data for quality improvement programs, operational optimization, population health management, clinical benchmarking, and medical research while ensuring regulatory compliance.
Regional Highlights
- Largest regional market: North America (35.3% revenue share, 2025)
- Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
- By country: The U.S. held the largest market share in 2025.
Market Size & Forecast
- Market Size (2025): USD 8.8 Billion
- Estimated Market Size (2026): USD 9.6 Billion
- Projected Market Size (2033): USD 17.9 Billion
- CAGR (2026-2033): 9.4%
The market is also benefiting from increasingly stringent global data privacy regulations, including HIPAA in the United States and GDPR across Europe, which encourage organizations to adopt secure de-identification practices for secondary healthcare data usage. Simultaneously, rapid advancements in machine learning, generative AI, medical imaging analytics, and predictive healthcare models are significantly increasing demand for high-quality, privacy-preserving datasets.
Looking for more specific insights? Customize this report to suite your business needs
Healthcare organizations are increasingly integrating data from electronic health records, genomics, diagnostic imaging, wearable devices, claims databases, and remote monitoring platforms into unified analytics environments. This convergence is enabling more comprehensive disease modeling, earlier diagnosis, precision medicine development, and healthcare resource optimization. As healthcare continues its digital transformation, de-identified health data is expected to become one of the most valuable assets supporting AI innovation, pharmaceutical research, and data-driven healthcare delivery.
Key De-identified Health Data Company Insights
Competition within the de-identified health data market continues to intensify as organizations expand partnerships, acquisitions, and technology collaborations to strengthen their analytics capabilities and healthcare data ecosystems. Companies are investing in AI-enabled data platforms, cloud-based healthcare analytics, interoperability solutions, and privacy-enhancing technologies to improve the quality, accessibility, and security of de-identified datasets.
For example, in September 2024, ICON plc partnered with IBM to enhance clinical trial operations through the use of de-identified health data. The collaboration focuses on improving patient recruitment, optimizing study design, accelerating drug development, and enabling more efficient clinical research while maintaining strict patient privacy standards.
Leading market participants are also expanding investments in real-world evidence platforms, AI-powered clinical research tools, federated data networks, and healthcare interoperability solutions to support pharmaceutical companies, healthcare providers, payers, and research organizations. As demand for privacy-compliant healthcare analytics continues to rise, innovation in secure data sharing and advanced analytics will remain central to competitive differentiation.
Key De-identified Health Data Companies
The following companies are among the leading participants in the global de-identified health data market:
- IQVIA
- Oracle (Cerner Corporation)
- Optum, Inc. (UnitedHealth Group)
- ICON plc
- Veradigm LLC (formerly Allscripts)
- IBM
- Flatiron Health (F. Hoffmann-La Roche Ltd.)
- Premier, Inc.
- Shaip
- Komodo Health, Inc.
- Evidation Health, Inc.
- Medidata
- Clarify Health Solutions
- Satori Cyber Ltd.
Conclusion
The de-identified health data market is entering a period of sustained expansion as healthcare organizations increasingly balance data accessibility with patient privacy. Rising adoption of AI, precision medicine, real-world evidence, and advanced healthcare analytics is driving demand for secure, compliant datasets that enable faster research, improved clinical outcomes, and more efficient healthcare delivery. With continuous advancements in privacy-enhancing technologies, cloud-based analytics, and collaborative healthcare ecosystems, de-identified health data is expected to play a foundational role in accelerating medical innovation, supporting regulatory compliance, and transforming data-driven healthcare worldwide.
Looking for a report customized to your requirements? Explore our Custom Research Offering
Grand View Research offers
- Focused market intelligence reports on specific geographies or high-growth segments
- Extended forecast timelines for long-term planning
- Competitor Benchmarking and Supply Chain Analysis
- Inclusion of regulatory and policy assessments
- Inclusion of custom data models, KPIs, or applications unique to your business
- Specific high-impact Data Decks and Tables to support effective decision making
And much more…
Indonesia
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek